Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? At this time, there is little in the way for combat-related PTSD treatment specifically. Let’s find out. .

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The Summit found that cannabis does not enhance athletic performance.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JULY 22, 2021

A master distribution agreement has been signed with My Green Planet, a leading global agricultural supply group, giving Sporeo access to approximately 7,000 retailers across North America, Australia, and Europe. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

SpeedWeed

MARCH 13, 2021

However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. . As a result, many patients turn to complementary or alternative treatments for their disease. . One such alternative treatment is cannabis.

Patients 52

Patients Treatment Therapy Sleep 52

Veriheal

SEPTEMBER 15, 2021

This is very important if we wish to see a day where cannabis has been removed from harsh drug scheduling and if we wish to see it become part of everyday treatment practices by professionals. . Non-Experimental Research: Observational study, or non-experimental research, focuses on analyzing data in its natural context.

Data 95

Data Collective Environment Cannabis 95

CannaMD

SEPTEMBER 15, 2020

SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. In March, 2016, State Bill 307 expanded access to full-strength medical marijuana to terminally ill patients who were determined by two doctors to have less than a year to live.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JANUARY 23, 2022

Events like these afford us a glimpse into the future of research and medicine in this field. At current, transplant treatments are hindered by our understanding of the immune response of those receiving treatments. The safety of CBD was noted even when administered in combination with the standard GVHD treatment.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

SEPTEMBER 23, 2021

The major concerns noted were adverse events following consumption (many from inadvertent intoxication), marketing to and use by minors, and the potential presence of harmful by-products and unsafe manufacturing practices. The FDA has received adverse event reports involving delta-8 THC-containing products. CDC Health Alert.

THC 52

THC Concentrates Pets DEA 52

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Accelerate adoption across a broader prescriber base. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Le-Short C.,

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding. Sesen Bio, Inc.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Veriheal

MAY 3, 2022

Kevin Potter taking responsibility for the integrity and accuracy of the data. a necessary question to address as medical marijuana becomes more accessible. The study also said that the participants could continue their usual treatments or psychiatric care but did not specify which conditions the patients had.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

NORML

MAY 24, 2019

At the same time, the bill would redirect tax revenue from a legal industry towards various programs that redress harms from the War on Drugs, while also increasing and improving public education and treatment programs geared towards responsible use, reducing overdoses, and saving lives.

Marijuana 103

Marijuana Education Advocacy Legislation 103

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Freedom Leaf

JANUARY 4, 2018

After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.

Data 60

Data Policy Media Cannabis 60

Veriheal

OCTOBER 5, 2020

This bill also allows for dispensaries to “provide, disseminate, and publish educational and scientific material related to medical cannabis and its approved products and sponsor events about medical cannabis”. . Summary of Hawaiian Cannabis Regulations. Act 228 allows for the growth of cannabis for medical purposes. .

Edibles 52

Edibles Legalization Decriminalization Consumption 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

SEPTEMBER 27, 2021

With the expected introduction of the adult-use cannabis program and loosening of the medical-use cannabis program restrictions, New Frontier Data projects that New York will be the second largest regulated cannabis market in the United States by 2025, behind only California. million rentable square feet (including approximately 2.9

Programs 52

Programs Patients Cultivation Dispensary 52

Cannabis Law Report

DECEMBER 14, 2021

“Columbia Care’s mission has always been to provide patients with access to the highest quality, safest medicinal cannabis products available. We are proud to leverage our proprietary IP, formulation expertise, safety surveillance and patient reported data from the U.S.

Extraction 52

Extraction Patients Medicine Tincture 52

CannaTech

MAY 16, 2019

CannaTech Tel Aviv 2019 was an absolute sensation, and we are already looking to Cape Town for our next big event. This revolutionary storage device maintains optimal conditions for cannabis freshness and potency, and makes monitoring, tracking, dispensing, and procuring medical cannabis accessible to everyday patients.

Data 13

Data Collective Consumption Treatment 13

Cannabis Law Report

MARCH 19, 2020

They expressed this concern at a public meeting held by FDA in May 2019, explaining that conflicting regulatory requirements create uncertainty that is stifling medical research and hindering consumer access to CBD products. The docket will be open indefinitely, allowing stakeholders to comment and share data with FDA on an ongoing basis.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

CannaMD

DECEMBER 9, 2020

The AHA statement raises questions on whether cannabis use plays a role in major cardiac events such as arrhythmia and heart attacks, but does not draw any definitive conclusions. Based on data from a 2020 study , it is estimated that 2 million of the 89.6 for men, 1.3% Find Out if You Qualify. Get Started. Join 70K+ Subscribers!

Marijuana 111

Marijuana Research and Development Consumption Vaping 111

Cannabis Law Report

MAY 6, 2022

Generally, a CBD product seller is expected (or required by law) to provide customers with access to a “certificate of analysis” or “COA” associated with specific products, which COA confirms the levels of CBD in products and upon which customers can rely. Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

The Cannigma

MARCH 25, 2021

When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. These qualities are necessary to ensure that the private medical cannabis space conducts itself with compassion and respect for those who are accessing medication through it.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

MARCH 2, 2022

Hear the tale of how Anthony came to work in the cannabis space, telling the stories of cannabis brands and making them accessible to non-users. We’ve got a segment with Americans for Safe Access, talking a little bit about regulation and some current affairs. Events are always easy to do, like live events.

Wellness and Beauty 52

Wellness and Beauty Cannabis Media Patients 52

CannaMD

MARCH 8, 2020

The study authors arrived at this estimate based on a series of user-response surveys, with the notation that “given the substantial non-response [to the survey questions] these data are subject to response bias.”. Acknowledging the limited scope of data, few mechanisms of cardiovascular risk have emerge. a heart attack).

Patients 79

Patients Marijuana Research and Development Clinical Trials 79